Shanghai Microport Lifesciences Co., Ltd. was established in Yigu Park, Shanghai International Medical Park on April 28, 2008. The company's main business is the research and development, production, and operation of various medical devices in the fields of endocrine management, chemotherapy, pain management, etc. The portfolio of products includes Class II and Class III (NMPA)medical devices such as insulin pumps, hypophyseal hormone pumps, and chemotherapy pumps, patient control analgesia(PCA) pump.
The company owns a R&D complex of more than 2,300 square meters and a modern production base of more than 3,000 square meters in the Medical Valley Modern Business Park in Pudong New Area. The company is equipped with sophisticated, highly automated processing equipment and testing equipment, modern laboratories, etc., and has a purification workshop of more than 1,000 square meters that meets national standards for the production of sterile medical device products.
The users of our products are cover 31 provinces of China and more than 800 hospitals, including more than 280 tertiary hospitals.
The chemotherapy pump was successfully approved to be included in the "Recommended Catalog of Innovative Pharmaceutical and Device Products in Pudong New Area" (first batch);
In April 2023, the company's first digital medical device, the hypophseal hormone pump, was approved for marketing by the National Medical Products Administration (NMPA);
In June 2023, the company's first approved product in pain management solutions - PCA pump: AutoEx® portable electric infusion pump, was approved for marketing by the National Medical Products Administration (NMPA);
On March 16, 2022, the company's first approved product in the intelligent chemotherapy solution, AutoEx® chemotherapy injection pump, was approved for marketing by the National Medical Products Administration (NMPA);
Passed the review of national high-tech enterprise qualifications;
Obtained the 2021 Shanghai "Specialized, Special and New" enterprise certification;
Obtained recognition as an enterprise R&D institution in Pudong New Area;
Obtained recognition as a pilot unit for patent work in Shanghai enterprises and institutions in 2022;
Completed over 100 million yuan in Series A financing.
Strategically deploy the field of glucose monitoring, establish a CGM R&D team, and deploy full ecosystem solutions for diabetes management.
Won the honorary title of National High-tech Enterprise for the first time;
The Hypophyseal hormone infusion pump developed in cooperation with Shanghai Ruijin Hospital has filled the gap in the field of pulse micro-infusion pumps in the treatment of Kallman Syndrome. It is the first of its kind in China.
The project won the first prize of the 2019 Shanghai Technology Invention Award;
Series A financing
Strategic investment in Zenomics, a US company with bio-intelligent responsive insulin infusion platform technology
The research and development project of tumor chemotherapy pump was established, officially entering the field of tumor equipment.
La Fenice Hypophyseal Hormone Pump was recognized as a high-tech achievement transformation project in Shanghai
La Fenice Hypophyseal Hormone Pump launched
Won the "2010 Best Call Center in China (Asia-Pacific)"
La Fenice insulin pump and consumables launched
Lifesciences was established and entered the field of diabetes management
La Fenice Type 2.0 insulin pump is primarily designed for treating diabetes. This device employs artificial intelligence-controlled insulin delivery, administering insulin continuously through subcutaneous infusion. This method mimics the physiological secretion of insulin, offering an intensified treatment approach to control high blood sugar levels. Resembling the size and shape of an MP3 player, the pump can be worn on the waist. Using a small needle placed under the skin, it delivers insulin in different ways, including basal rates and pre-meal doses, continuously over 24 hours. The pump simulates the insulin secretion curve of normal human islet, and the control effect of glycemia is smoother than multiple daily injection with insulin pen or syringe. Based on the previous generation, the 2.0 model has added Bluetooth connection and alternative control functions, making it convenient for users to check and set the insulin pump on the large screen of their phones. In the future, it will be part of artificial pancreas with a continuous glucose monitor system and closed-loop control algorithm.
The AutoEx® Chemotherapy Pump is clinically used for the continuous or intermittent infusion of drugs during chemotherapy in cancer patients. It consists of a driving device and disposable pump infusion device. The driving device primarily comprises a main control system, motor movement system, power supply system, detection system, human-computer interaction system, and alarm system. Equipped with a dual-CPU control system and dual power supply, the driving device ensures high-precision drug administration control, enhancing patient comfort in a safe and reliable manner.
The disposable of pump includes two liquid storage bags. This innovative design allows for automatic flushing or sealing through various implanted central venous catheters. After the completion of chemotherapy drug infusion from liquid storage bag 1, the device can intelligently switch according to the set program, reducing the need for manual flushing or sealing by healthcare professionals. This feature helps conserve nursing resources in medical institutions.
The Analgesic pump is a commonly used micro-infusion device in clinical anesthesia, controlled by a computer, and employed for perioperative pain relief. It provides significant assistance in postoperative pain management and other medical applications. Compared to traditional single-dose pain relief methods, the electronic Analgesic pump allows for precise and personalized patient-controlled analgesia. It uses smaller medication doses, offers better pain relief, and has higher safety levels. Additionally, it can help reduce the development of resistance and addictive side effects associated with potent opioid drugs like fentanyl and morphine. The pump is equipped with various safety warning mechanisms to effectively prevent and detect infusion malfunctions, including blockages.
The Analgesic pump comprises three parts: the driving device, patient-controlled fluid delivery device, and disposable pump infusion device. The driving device consists of a main control system, motor movement system, power supply system, detection system, human-computer interaction system, and alarm system. It features an intelligent operating interface that is user-friendly and integrates multiple sensors with real-time monitoring capabilities, enabling timely detection of anomalies and issuing alarms. The patient-controlled fluid delivery device includes an internal control fluid module and an externally connected patient-control handle. The disposable pump infusion device consists of a liquid storage bag, a rigid protective shell, and connecting tubing.
Endocrine Solutions takes insulin infusion platform as the core, extending the two directions of insulin treatment for diabetes and other endocrine hormone treatment . The former includes glucose monitoring, insulin dosage decision algorithms, infusion equipment, and digital management platforms in insulin therapy. Other endocrine hormone therapy applications include hypothalamic human GnRH (gonadotropin-releasing hormone) therapy for endocrine infertility.
Chemotherapy Solutions starts with chemotherapy drug infusion and expands to 2 types of medical devices: chemotherapy pumps and chemotherapy infusion access. In the future, we will supplement the development of infusion management software to enhance infusion safety and management capabilities.
Pain management Solutions is centered around the PCA pump, which is used to treat postoperative pain, childbirth pain, cancer pain, and continuous block analgesia.。
©Copyright 1998-2023, MicroPort Scientific Corporation. All rights reserved. | 网站备案/许可证号:沪ICP备06056186号 沪公网安备 31011502014876号
互联网药品信息服务资格证书编号:(沪)-非经营性-2023-0275
“微创”、“MicroPort”及“ ”为我司注册商标,未经许可不得擅自使用。